Chronic Kidney Disease and its Complications

Author(s)

Dr Mujtaba Ali Hasnain , Dr Muhammad Fahad Ali , Dr Zubair Anwar ,

Download Full PDF Pages: 01-05 | Views: 731 | Downloads: 160 | DOI: 10.5281/zenodo.3974427

Volume 9 - July 2020 (07)

Abstract

High quality epidemiological studies conducted in different regions of the world revealed that at present 12 to 13% adult individuals have chronic kidney disease markers. The young population is prone to this complex disease at a very high rate. The progression of CKD is linked with the already existing a number of complications like diabetes, cardiovascular disease, hyperlipidemia, anemia and metabolic disorders. In CKD, the patient’s kidneys fail to filter the blood at normal rate and this leads to accumulation of waste materials in the body and toxicity. If CKD isn’t treated well on time, then it increases the morbidity and mortality rate. A multidisciplinary approach is required to combat this situation, especially in the developing countries like Pakistan, where resources are limited and healthcare institutes fail to provide adequate dialysis and patient management as per recommended guidelines. This review paper throws light on the chronic disease and its complications.

Keywords

Chronic Kidney Disease

References

    i.            Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama-Journal of the American Medical Association. 2007;298:2038–2047. [PubMed] [Google Scholar]

    ii.            KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am.J.Kidney Dis. 2006;47:S11–S145. [PubMed] [Google Scholar]

  iii.            Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2005;67:2089–2100. [PubMed] [Google Scholar]

  iv.            Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases. 2003;41:1–12. [PubMed] [Google Scholar]

    v.            Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann.Intern.Med. 2004;141:95–101.

  vi.            Muzzarelli S, Pfisterer M. Anemia as independent predictor of major events in elderly patients with chronic angina. Am.Heart J. 2006;152:991–996. [PubMed] [Google Scholar]

vii.            Fink J, Blahut S, Reddy M, et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am.J.Kidney Dis. 2001;37:348–355. [PubMed] [Google Scholar]

viii.            Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N.Engl.J.Med. 1998;339:584–590. [PubMed] [Google Scholar]

  ix.            Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N.Engl.J.Med. 2006;355:2085–2098. [PubMed] [Google Scholar]

    x.            Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol.Dial.Transplant. 2003;18 Suppl 2:ii7–ii12. [PubMed] [Google Scholar]

  xi.            Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am.J.Health Syst.Pharm. 2007;64:S3–S7.

xii.            Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N.Engl.J.Med. 2005;353:238–248. [PubMed] [Google Scholar]

xiii.            Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney International. 2002;61:1887–1893. [PubMed] [Google Scholar]

xiv.            Eknoyan G, Levin A, Levin N. K/DOQ1 clinical practice guidelines for managing dyslipidemias in chronic kidney disease. American Journal of Kidney Diseases. 2003;41:S6–S91. [Google Scholar]

 xv.            Cleeman JI, Grundy SM, Becker D, et al. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Jama-Journal of the American Medical Association. 2001;285:2486–2497. [PubMed] [Google Scholar]

xvi.            Appel GB, Blum CB, Chien S, et al. The Hyperlipidemia of the Nephrotic Syndrome - Relation to Plasma-Albumin Concentration, Oncotic Pressure, and Viscosity. New England Journal of Medicine. 1985;312:1544–1548. [PubMed] [Google Scholar]

xvii.            Khan IH, Catto GRD, Edward N, et al. Death During the First 90 Days of Dialysis - A Case-Control Study. American Journal of Kidney Diseases. 1995;25:276–280. [PubMed] [Google Scholar]

xviii.            Herrmann FR, Safran C, Levkoff SE, et al. Serum-Albumin Level on Admission As A Predictor of Death, Length of Stay, and Readmission. Archives of Internal Medicine. 1992;152:125–130.

Cite this Article: